Short QT Syndrome

⚡ Short QT Syndrome (SQTS) is a rare but potentially lethal inherited cardiac channelopathy that predisposes to sudden cardiac death (SCD), syncope, and atrial fibrillation (AF). It is characterised by an abnormally short QT interval (< 320 ms) on ECG due to accelerated myocardial repolarisation. First described in the early 2000s, SQTS has since been recognised as a significant cause of unexplained cardiac arrest in young, apparently healthy individuals. 💔 The condition is genetically heterogeneous — several mutations in potassium channel genes increase repolarising current, shortening the cardiac action potential duration. 🔬

🩺 Clinical Features

• 😵‍💫 Syncope: Common presenting symptom, often triggered by exertion, stress, or at rest during vagal surges. Results from self-terminating ventricular tachyarrhythmia.
• 💔 Sudden Cardiac Death (SCD): May be the first manifestation, particularly during sleep or exercise. Mechanism: ventricular fibrillation due to shortened refractory period.
• ❤️‍🔥 Atrial Fibrillation (AF): Frequently occurs early in life; may be paroxysmal or persistent. Reflects atrial shortening of repolarisation.
• 👨‍👩‍👧 Family History: Unexplained young sudden deaths or ICD implants in relatives strongly suggest inherited channelopathy.
• 🧍‍♂️ Asymptomatic Carriers: May be incidentally diagnosed on ECG during screening or pre-sports evaluations.

🧠 Pathophysiology

• Myocardial repolarisation (phase 3 of the action potential) is abnormally accelerated due to gain-of-function mutations in potassium channel genes.
• This results in a shortened refractory period, promoting re-entry and arrhythmogenesis in both atria and ventricles.
• Unlike Long QT Syndrome (LQTS), where delayed repolarisation leads to early after-depolarisations, SQTS promotes re-entry tachycardia and fibrillation by reducing dispersion of refractoriness.

🧬 Genetics

• 🧩 Genetic Heterogeneity: SQTS is inherited in an autosomal-dominant pattern with variable penetrance.
• 🧬 KCNH2 (HERG, SQTS1): Gain-of-function mutation → increased I_Kr current → shortened QT interval.
• 🧬 KCNQ1 (SQTS2): Increases I_Ks current, accelerating repolarisation.
• 🧬 KCNJ2 (SQTS3): Mutation in Kir2.1 → increased I_K1 inward rectifier → shortened action potential plateau.
• Less common genes: SLC4A3, CACNA1C, CACNB2b (linked to mixed Brugada/SQTS phenotypes).
• Family screening via cascade genetic testing is recommended when a pathogenic variant is identified. 👨‍👩‍👧‍👦

📊 Diagnosis

• 📉 QTc interval < 320 ms (sometimes 330 ms as threshold) on resting ECG.
• 👉 QT not adapting to heart rate: In SQTS, QT remains abnormally short even at low heart rates.
• 🔄 Absence of secondary causes: Exclude hypercalcaemia, hyperkalaemia, acidosis, digoxin toxicity, and hypothermia.
• 📚 Diagnostic Score: Gollob et al. (2011) proposed a scoring system incorporating QT duration, family history, symptoms, and genotype.
• ⚡ ECG features: Short QT, peaked T waves, short or absent ST segment, and abbreviated ventricular repolarisation phase.

🩺 Differential Diagnosis

• Long QT Syndrome (opposite phenotype)
• Hypercalcaemia, Hyperkalaemia
• Digitalis effect
• Early repolarisation syndrome
• Brugada syndrome (may coexist genetically)

💊 Management

• ⚡ Implantable Cardioverter-Defibrillator (ICD): Mainstay for secondary prevention (patients with SCD, VF, or syncope). Provides immediate defibrillation in recurrent VF.
• 💊 Pharmacological Options:
  • Quinidine (Class Ia antiarrhythmic) prolongs QT by blocking I_Kr and I_to; effective in some genotypes (especially KCNH2-related).
  • Sotalol and disopyramide have variable efficacy.
• 🧍‍♂️ Asymptomatic Carriers: Observation and periodic ECG monitoring; consider prophylactic quinidine if QT < 300 ms or strong family history.
• 💉 Family Screening: First-degree relatives should undergo ECG and, if possible, genetic testing.
• 🏃‍♂️ Lifestyle: Avoid drugs that further shorten QT (e.g. digoxin, hypercalcaemia-inducing agents). No contraindication to exercise if stable and monitored.

📈 Prognosis

• Without treatment, risk of SCD may exceed 30% by mid-adulthood.
• With ICD or effective pharmacotherapy, survival approaches normal life expectancy.
• Recurrence risk highest in individuals with QTc < 300 ms and family history of SCD.

📚 References

• 🧬 Short QT Syndrome: From Bench to Bedside – Review (PMC)
• Gollob MH et al., Circulation 2011 ;123:484–495 – Diagnostic Criteria and Management.
• Giustetto C et al., J Am Coll Cardiol 2006 ;47:807–814 – Natural History and ECG Characteristics.

💡 Teaching Tip: When you see a very short QT interval (≤ 320 ms) with tall, peaked T waves — think Short QT Syndrome! Always ask about family history of sudden death or unexplained syncope. Differentiate from electrolyte causes and remember: ICD saves lives 🫀⚡